Photo credit: Jacquelyn Martin

Where are the in­ter­change­able biosim­i­lars?

In June 2017, Leah Christl, for­mer biosim­i­lar lead at FDA, told a con­fer­ence in Chica­go that in­ter­change­able biosim­i­lars were like­ly com­ing to the US mar­ket with­in two years.

And al­though no in­ter­change­able biosim­i­lar has been ap­proved by FDA yet, and Christl has since moved on to Am­gen, progress on in­ter­change­able biosim­i­lars has been slow in the in­ter­ven­ing years.

Most re­cent­ly, Boehringer In­gel­heim an­nounced that it has com­plet­ed, as of last April, a switch­ing study nec­es­sary for launch­ing an in­ter­change­able biosim­i­lar for Hu­mi­ra (adal­i­mum­ab), al­though the com­pa­ny did not of­fer any fur­ther de­tails on the tim­ing of its sub­mis­sion to FDA or whether there will be an ad­vi­so­ry com­mit­tee to re­view the da­ta. Boehringer al­ready has an adal­i­mum­ab biosim­i­lar ap­proved by FDA, which it will launch in the US on 1 Ju­ly 2023.

In ad­di­tion, next March, in­sulin prod­ucts will make the tran­si­tion from be­ing reg­u­lat­ed un­der the FD&C Act to the PHS Act, which, ac­cord­ing to for­mer FDA Com­mis­sion­er Scott Got­tlieb means in­ter­change­able in­sulin prod­ucts are like­ly com­ing. FDA held a meet­ing in May on in­ter­change­able in­sulins, which will be par­tic­u­lar­ly im­por­tant as on­ly three fol­low-on in­sulin prod­ucts — Basaglar, Lus­duna and Ad­mel­og — have been ap­proved since 2015.

But out­side of the one po­ten­tial adal­i­mum­ab in­ter­change­able and sev­er­al pos­si­ble in­sulin in­ter­change­able prod­ucts (none of which have been pub­licly dis­closed), no oth­er com­pa­nies have even dis­closed be­gin­ning a switch­ing study. And al­though how such switch­ing stud­ies nec­es­sary for achiev­ing this des­ig­na­tion was on­ly fi­nal­ized last May, with FDA’s guid­ance on biosim­i­lar in­ter­change­abil­i­ty, com­pa­nies have known about the switch­ing study re­quire­ments since at least when the draft was re­leased in Jan­u­ary 2017.

Bern­stein an­a­lyst Ron­ny Gal told Fo­cus via email that Am­gen and San­doz have said they will pur­sue in­ter­change­able biosim­i­lars but switch­ing stud­ies have not list­ed yet.

Got­tlieb al­so said re­cent­ly in an in­ter­view that he be­lieves the use of switch­ing stud­ies to get an in­ter­change­abil­i­ty claim “is fair­ly ef­fi­cient, but I think there’s things that you can con­tin­ue to look at in terms of us­ing re­al-world ev­i­dence [RWE] and look­ing at how you struc­ture those switch­ing stud­ies to po­ten­tial­ly make it more ef­fi­cient.”

An­tho­ny Maf­fia, head of reg­u­la­to­ry af­fairs, North Amer­i­ca at San­doz, told Fo­cus in a phone in­ter­view that he agrees with Got­tlieb on the pos­si­ble use of RWE, “but the way it’s ap­plied needs flush­ing out.”

He al­so said he thinks the in­ter­change­abil­i­ty des­ig­na­tion is “cre­at­ing an ad­di­tion­al bar­ri­er to ac­cess, and we keep em­pha­siz­ing that and feel strong­ly that it’s unique to the US and sets us apart from oth­er glob­al health au­thor­i­ties.”

A lot of the dis­cus­sion on the sav­ings from biosim­i­lars is al­so cen­tered on the fact that state phar­ma­cy laws (45 states and Puer­to Ri­co have passed leg­is­la­tion, ac­cord­ing to Am­gen) stip­u­late that biosim­i­lars may on­ly be sub­sti­tut­ed at the phar­ma­cy if FDA has des­ig­nat­ed them as in­ter­change­able to their ref­er­ence prod­ucts.

“Un­less and un­til we change the way we pay for drugs more broad­ly, in­ter­change­ables are re­al­ly the cen­tral path to re­al com­pe­ti­tion and low­er prices,” Aaron Kessel­heim, di­rec­tor of the Pro­gram on Reg­u­la­tion, Ther­a­peu­tics and Law at Brigham and Women’s Hos­pi­tal, Har­vard Med­ical School, pre­vi­ous­ly ex­plained to Fo­cus.

But many bi­o­log­ics are ad­min­is­tered by physi­cians so the in­ter­change­abil­i­ty des­ig­na­tion will like­ly not be pur­sued in those in­stances. Oth­ers al­so have said in­ter­change­ables will not nec­es­sar­i­ly hit the mar­ket with as large of a dis­count as biosim­i­lars with­out the des­ig­na­tion.

In ad­di­tion, there is a lot of room for mis­in­for­ma­tion among phar­ma­cists and doc­tors. Hil­lel Co­hen, ex­ec­u­tive di­rec­tor of sci­en­tif­ic af­fairs at San­doz, pre­vi­ous­ly ex­plained how an in­ter­change­able biosim­i­lar is not more high­ly sim­i­lar than a non-in­ter­change­able biosim­i­lar, al­though the des­ig­na­tion may pro­vide the false per­cep­tion of a bet­ter prod­uct.

Maf­fia added that he thinks FDA “ab­solute­ly” must clar­i­fy when cer­tain com­pa­nies are spread­ing mis­in­for­ma­tion on biosim­i­lars. “We have to get to a com­mon set of lan­guage and that’s some­thing that FDA has a role in,” he said.


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

A New Fron­tier: The In­ner Ear

What happens when a successful biotech venture capitalist is unexpectedly diagnosed with a chronic, life-disrupting vertigo disorder? Innovation in neurotology.

That venture capitalist was Jay Lichter, Ph.D., and after learning there was no FDA-approved drug treatment for his condition, Ménière’s disease, he decided to create a company to bring drug development to neurotology. Otonomy was founded in 2008 and is dedicated to finding new drug treatments for the hugely underserved community living with balance and hearing disorders. Helping patients like Jay has been the driving force behind Otonomy, a company heading into a transformative 2020 with three clinical trial readouts: Phase 3 in Ménière’s disease, Phase 2 in tinnitus, and Phase 1/2 in hearing loss. These catalysts, together with others in the field, highlight the emerging opportunity in neurotology.
Otonomy is leading the way in neurotology
Neurotology, or the treatment of inner ear neurological disorders, is a large and untapped market for drug developers: one in eight individuals in the U.S. have moderate-to-severe hearing loss, tinnitus or vertigo disorders such as Ménière’s disease.1 With no FDA-approved drug treatments available for these conditions, the burden on patients—including social anxiety, lower quality of life, reduced work productivity, and higher rates of depression—can be significant.2, 3, 4

Joe Jimenez, Getty

Ex-No­var­tis CEO Joe Jimenez is tak­ing an­oth­er crack at open­ing a new chap­ter in his ca­reer — and that in­cludes a new board seat and a $250M start­up

Joe Jimenez is back.

The ex-CEO of Novartis has taken a board seat on Century Therapeutics, the Versant and Bayer-backed startup focused on coming up with a brand new twist on cell therapies for cancer — a field where Jimenez made his mark backing the first personalized CAR-T approved for use.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,700+ biopharma pros reading Endpoints daily — and it's free.

Credit: Shutterstock

Can we make the an­tibi­ot­ic mar­ket great again?

The standard for-profit model in drug development is straightforward. Spend millions, even billions, to develop a medicine from scratch. The return on investment (and ideally a tidy profit) comes via volume and/or price, depending on the disease. But the string of big pharma exits and slew of biotech bankruptcies indicate that the model is sorely flawed when it comes to antibiotics.

The industry players contributing to the arsenal of antimicrobials are fast dwindling, and the pipeline for new antibiotics is embarrassingly sparse, the WHO has warned. Drugmakers are enticed by greener pastures, compared to the long, arduous and expensive path to antibiotic approval that offers little financial gain as treatments are typically priced cheaply, and often lose potency over time as microbes grow resistant to them.

Amber Saltzman (Ohana)

Flag­ship's first ven­ture of 2020 is out, and it's all about sperm

A couple years ago, Amber Salzman got a call as she was returning East full-time after a two-year stint running a gene therapy company in California.

It was from someone at Flagship Pioneering, the deep-pocketed biotech venture firm. They had a new company with a new way of thinking about sperm. It had been incubating for over a year, and now they wanted her to run it.

“It exactly fit,” Salzman told Endpoints News. “I just thought I had to do something.”

The FTC and New York state ac­cuse Mar­tin Shkre­li of run­ning a drug mo­nop­oly. They plan to squash it — and per­ma­nent­ly ex­ile him

Pharma bro Martin Shkreli was jailed, publicly pilloried and forced to confront some lawmakers in Washington riled by his move to take an old generic and move the price from $17.50 per pill to $750. But through 4 years of controversy and public revulsion, his company never backed away from the price — left uncontrolled by a laissez faire federal policy on a drug’s cost.

Now the FTC and the state of New York plan to pry his fingers off the drug once and for all and open it up to some cheap competition. And their lawsuit is asking that Shkreli — with several years left on his prison sentence — be banned permanently from the pharma industry.

UP­DAT­ED: Ac­celeron res­ur­rects block­buster hopes for so­tater­cept with pos­i­tive PhII — and shares rock­et up

Acceleron $XLRN says that its first major trial readout of 2020 is a success.

In a Phase II study of 106 patients with pulmonary arterial hypertension (PAH), Acceleron’s experimental drug sotatercept hit its primary endpoint: a significant reduction in pulmonary vascular resistance. The drug also met three different secondary endpoints, including the 6-minute walking test.

“We’re thrilled to report such positive topline results from the PULSAR trial,” Acceleron CEO Habib Dable said in a statement. The company said in a conference call they plan on discussing a Phase III trial design with regulators.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,700+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er ax­es 6 ear­ly to late-stage can­cer stud­ies from the pipeline — with one oth­er cut for sick­le cell dis­ease

Pfizer trimmed a group of 3 R&D programs using their PD-L1 Bavencio — partnered with Merck KGaA — in their latest pipeline cull.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,700+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: In­cyte scores much need­ed PhI­II suc­cess — and of course it’s de­liv­ered by rux­oli­tinib

Incyte’s efforts to breathe a second life into ruxolitinib — its JAK inhibitor sold in pill form as Jakafi — has been greeted with clear, if preliminary and unsurprising, Phase III success.

Topline data from the TRuE-AD2 cements ruxolitinib’s foundational importance for Incyte, and gives analysts hope that there might yet be room for growth in a pipeline that’s suffered multiple R&D setbacks.

Stephen Hahn, AP

The FDA un­veils a new reg­u­la­to­ry frame­work to speed along gene ther­a­pies, re­ward­ing the lead­ing play­ers

Bioregnum Opinion Column by John Carroll

The emphasis at the FDA over the past 5 years or so has been on assisting drug developers as much as they can to speed up regulatory reviews and push more drugs into the market. And they are now crafting a final set of regulations aimed at flagging through a whole new generation of gene therapies in clinical testing at a rapid clip.

In a set of 6 prospective guidances posted on the FDA web site Tuesday morning, FDA commissioner Stephen Hahn committed the agency to staying flexible in handing out designations that are critical to gaining early approvals for drugs that claim to be once-and-done but don’t have anything close to the data needed to prove it.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.